Source:http://linkedlifedata.com/resource/pubmed/id/16469868
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2006-5-4
|
pubmed:abstractText |
The Bcr-Abl oncoprotein plays a major role in the development and progression of chronic myeloid leukemia (CML). Several studies have suggested that the expression levels of Bcr-Abl are elevated at disease progression to blast crisis and that this plays a significant role in the achievement of drug resistance. We have established cell lines expressing low and high levels of Bcr-Abl to study the molecular mechanisms involved in disease progression and drug resistance. It is now known that the endoplasmic reticulum (ER) can play a major role in the regulation of apoptosis. We therefore investigated whether Bcr-Abl expression modulates ER homeostasis and interferes with ER-mediated apoptotic pathways to promote survival. Bcr-Abl-expressing cells exhibit a decreased amount of free releasable calcium in the ER as well as a weaker capacitative calcium entry response, relative to parental cells. This effect is independent of Bcl-2, which is a known modulator of ER calcium homeostasis. The reduction in ER releasable calcium results in inhibition of the ER/mitochondria-coupling process and mitochondrial calcium uptake. This study demonstrates a novel downstream consequence of Bcr-Abl signaling. The ability to negate calcium-dependent apoptotic signaling is likely to be a major prosurvival mechanism in Bcr-Abl-expressing cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
107
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
4003-10
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:16469868-Apoptosis,
pubmed-meshheading:16469868-Calcium,
pubmed-meshheading:16469868-Cell Survival,
pubmed-meshheading:16469868-Endoplasmic Reticulum,
pubmed-meshheading:16469868-Fusion Proteins, bcr-abl,
pubmed-meshheading:16469868-Humans,
pubmed-meshheading:16469868-In Situ Nick-End Labeling,
pubmed-meshheading:16469868-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:16469868-RNA, Small Interfering,
pubmed-meshheading:16469868-Signal Transduction,
pubmed-meshheading:16469868-Transfection
|
pubmed:year |
2006
|
pubmed:articleTitle |
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling.
|
pubmed:affiliation |
Department of Biochemistry, BioSciences Institute, University College Cork, Cork, Ireland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|